| Code | CSB-RA015007MB17HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Ripertamab, targeting MS4A1 (Membrane Spanning 4-Domains A1), also known as CD20. MS4A1 is a cell surface phosphoprotein exclusively expressed on B lymphocytes from the pre-B cell stage through mature B cells, but absent on plasma cells. This transmembrane protein plays a crucial role in regulating B-cell activation, proliferation, and differentiation through modulation of calcium influx and cell cycle progression. MS4A1 is critically implicated in various B-cell malignancies including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and B-cell acute lymphoblastic leukemia, as well as autoimmune disorders such as rheumatoid arthritis and multiple sclerosis.
Ripertamab is a therapeutic monoclonal antibody designed to bind MS4A1 and induce B-cell depletion through complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and direct apoptosis induction. This biosimilar antibody serves as a valuable research tool for investigating B-cell biology, immune system mechanisms, and the pathophysiology of B-cell-related disorders, enabling studies of MS4A1-mediated signaling pathways and therapeutic mechanisms.
There are currently no reviews for this product.